Sensyne Health plc, the British Clinical AI technology company, recently announced that in response to new UK government guidelines for all pregnant women to avoid face-to-face contact for three months, it will be providing its GDm-Health digital therapeutic product free to NHS Trusts for one year.
GDm-Health is a digital therapeutic for the remote management of women with diabetes during pregnancy by their clinical care team. Comprising a smartphone application connected to a wireless blood glucose monitor, the patient’s near real-time data that has been prioritised by algorithms. This is communicated directly to the hospital team supervising care, enabling this high-risk group to monitor their condition safely at home.
GDm-Health is regulated, CE marked and clinically validated and can be rapidly deployed. Already commercially available and in-use at 16 NHS trusts, Sensyne Health will work collaboratively with the NHS to broaden the use of the product.
Lord (Paul) Drayson, CEO of Sensyne Health, said: “In light of the UK government’s guidelines around ‘social distancing’ to combat the ongoing COVID-19 pandemic, there is now a greater focus than ever before on the use of remote patient monitoring to reduce the burden on limited NHS resources and help high-risk people stay at home.
“Providing this product free of charge during the pandemic will enable the NHS to adopt GDm-Health quickly and provide remote care for more pregnant women during this crucial time and hence reduce hospital visits for this high-risk group.
“We are also working closely with our NHS partners as well as our industry collaborators on modifying our existing technologies to aid remote patient monitoring and provide the authorities with additional relevant information on the pandemic.”
Lucy Mackillop , Chief Medical Officer of Sensyne Health plc and consultant obstetric physician at Oxford University Hospitals NHS Foundation Trust and Honorary Senior Clinical Lecturer, Nuffield Department of Women’s and Reproductive Health, University of Oxford, said: “